USANA Health Sciences account plan
Science-driven nutritional supplement company
At a glance
USANA Health Sciences makes science-based nutritional supplements sold by direct selling and Hiya, with $925.3 million FY2025 net sales.
USANA Health Sciences (NYSE: USNA, Salt Lake City, Utah) develops and manufactures science-based nutritional supplements, functional foods and personal care products. It historically sold only through independent Brand Partners and Preferred Customers, and now runs an omni-channel platform after acquiring Rise and a 78.85% stake in Hiya Health Products: direct selling, direct-to-consumer, Amazon and retail. FY2025 net sales were $925.3 million (+8.3%), but net earnings attributable to USANA fell 74.4% to $10.8 million; China was approximately 41.3% of net sales. It had approximately 1,570 employees (FTE) in 22 countries.
Business units
Core Nutritional
$775.5 million, 83.8% of FY2025 net salesUSANA-branded supplements, foods and Celavive skincare sold through Brand Partners and Preferred Customers, 90.8% outside the United States; Greater China is the largest region. Active Customers fell to approximately 356,000 in Q3 2026 (-8.2%), and Q3 2026 sales were $170.7 million (-3.1%).
Hiya
$132.0 million, 14.3% of FY2025 net salesChildren's vitamins sold mainly by subscription in the United States, now also in Canada, the UK, Target and Amazon. Q3 2026 sales rose 2.3% to $31.5 million with approximately 195,500 active Monthly Subscribers; a $29.1 million goodwill impairment was taken in Q2 2026.
Rise
$20.7 million nine-month 2026 net salesProtein bars and protein drinks, including Protein Pop (68% of Rise sales), sold to national and club retailers. Nine-month sales rose 94.4%, but Q3 2026 sales fell 44.8% to $3.6 million and the outlook was lowered as club orders were lumpy.
Strategic priorities
- Omnichannel transformation
- Management aims to evolve USANA from a single channel direct selling company into a diversified omnichannel health and wellness company, which it also frames as reducing dependence on China.
- Grow active customers
- Growing the active customer base is the top priority, through brand investment, Brand Partner plan adjustments phased in through 2027, and women's and kids' product launches in 2027.
- Technology modernisation and AI
- USANA plans to modernise core systems by adopting best-in-practice third-party platforms and to use AI, rather than building everything in-house.
- Scale Hiya and Rise
- Hiya's sales outlook was raised to $130 million with club retail entry planned early Q1 2027; Rise will be in about 4,100 Target and grocery stores by year end.
- Operational efficiency
- The Q4 2025 cost realignment affected about 10% of the workforce for roughly $10 million of net savings, and more manufacturing is being brought in-house.
Latest results
In Q3 2026 (quarter ended October 3, 2026), net sales fell 3.6% to $205.9 million (5.6% excluding currency) and the net loss attributable to USANA was $5.6 million, or $(0.30) per diluted share. Core Nutritional sales fell 3.1% while Hiya grew 2.3% and Rise fell 44.8%. Nine-month net sales were $679.4 million, with a diluted loss per share of $(1.05) mainly due to the Hiya goodwill impairment. The FY2026 outlook is net sales approaching $900 million and adjusted EBITDA of approximately $77 million, down from $80.5 million.
Investments and deals
- In-house manufacturing
- Hiya products and powdered drink mixes are moving into USANA's own facilities, with more personal care and skincare made in-house.
- Inventory for retail expansion
- Inventory rose $35 million to $107 million at the end of 2025, about 80% of it for Rise (Protein Pop at Costco) and Hiya (Target, Canada, UK).
- Castle Hill sale
- The sale of the Castle Hill, New South Wales office and warehouse settled October 12, 2026, with an estimated pre-tax gain of $8,230 thousand in Q4 2026.
- Acquisitions
- USANA expects to keep pursuing health and wellness acquisitions for vertical integration, category, channel and geographic expansion.
Challenges and risks
- Shrinking core customer base
- Core nutritional active Customers fell 14.8% in FY2025 and 8.2% in Q3 2026, with every region outside Southeast Asia Pacific declining in constant currency.
- China dependence and regulation
- Greater China is the largest market, BabyCare's model has not been approved by the Chinese government, and US-China tensions and tariffs are named risks.
- High tax rate
- The effective tax rate was 72.4% in FY2025 because revenue and costs sit in different geographies; guidance for 2026 was 55%-60%.
- Venture profitability
- Hiya's SG&A rose to 86.2% of segment sales on advertising, and Rise had a negative gross margin in Q3 2026; management is not satisfied with Rise's results.
What leadership says
“we must move with greater speed, focus, relevancy, and precision”
“Growing our active customer base remains our top priority.”
“we're not satisfied with Rise Wellness' results”
Where a supplier can help
- Third-party IT platforms and AI
- Core-system modernisation explicitly favours outside platforms and AI, opening doors for commerce, CRM, ERP and AI vendors.
- Customer acquisition and retention
- Growing active customers and Hiya subscriber retention are top priorities; loyalty, marketing analytics and digital acquisition tools fit.
- Retail and club distribution
- Hiya and Rise expansion into Target, Costco and club stores, with lumpy orders, calls for retail execution and demand-planning support.
- Manufacturing and supply chain
- Bringing Hiya and other products in-house and managing elevated inventory create needs for equipment, packaging and inventory tools.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like USANA Health Sciences?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- USANA Health Sciences Form 10-K for fiscal year 2025 (ended January 3, 2026)
- USANA develops and manufactures science-based nutritional supplements, functional foods and personal care products; FY2025 net sales were $925.3 million (+8.3%), with operations in 25 geographic markets and approximately 1,570 employees (FTE) in 22 countries.
- Two reportable segments in FY2025: Core nutritional (direct selling via Brand Partners and Preferred Customers, $775.5 million, 83.8% of sales) and Hiya direct-to-consumer (children's vitamins, $132.0 million, 14.3%); an "other" category (Rise protein bars/drinks and Oola) added $17.8 million (segment figures rounded from the 10-K tables in thousands).
- China is the largest market: approximately 41.3% of net sales and 49.9% of core nutritional active Customers; net sales outside the United States were 75.7% of consolidated net sales.
- Core business shrinking: core nutritional active Customers fell 14.8% to approximately 387,000; core net sales (with other) were $793.3 million, down 6.9%, partly offset by a 4.4% increase in average spend per customer.
- Profitability fell sharply: earnings from operations 4.0% of sales (7.7% in 2024); net earnings attributable to USANA down 74.4% to $10.8 million; diluted EPS $0.58 vs $2.19; effective tax rate 72.4%.
- Q4 2025 cost realignment and rightsizing: one-time charge of $6,463 thousand, plus a $6,527 thousand non-cash goodwill impairment.
- Strategy: move from a single direct-selling channel to an omni-channel platform (direct selling, direct-to-consumer, Amazon, retail); enhanced Brand Partner Compensation Plan rolled out in Q3 2025; Hiya expanding into Canada, the UK and retail in 2026, with Hiya products moving to in-house manufacturing.
- Technology: plans to accelerate modernisation of core systems and to "strategically leverage leading third-party IT platforms to move faster and more efficiently".
- Leadership: Kevin Guest reassumed the CEO role in January 2026 and remains Chairman; G. Douglas Hekking is CFO, Walter Noot COO, Brent Neidig Chief Commercial Officer, Kathryn Armstrong Chief Scientific Officer.
- Key risks: China direct-selling regulation (BabyCare's model has not been approved by the Chinese government), US-China trade tensions and tariffs, currency, Brand Partner retention, and integration of acquisitions such as Hiya.
- USANA Health Sciences Form 10-Q for Q3 2026 (quarter ended October 3, 2026)
- Q3 2026 net sales $205.9 million, down 3.6% (down 5.6% excluding currency); net loss attributable to USANA $5.6 million vs $6.5 million a year earlier; diluted loss per share $(0.30).
- USANA now reports three segments: Core Nutritional (approximately 83% of nine-month sales), Hiya and Rise.
- Core Nutritional Q3 net sales $170.7 million, down 3.1% (5.5% in constant currency); active Customers down 8.2% to approximately 356,000, with Greater China at 192,000 (-8.6%).
- Hiya Q3 net sales $31.5 million, up 2.3%; approximately 195,500 active Monthly Subscribers; Hiya now sells in the US, Canada and the UK and entered retail in Q1 2026; a $29.1 million non-cash goodwill impairment was taken on Hiya in Q2 2026.
- Rise Q3 net sales $3.6 million, down 44.8%, but nine-month sales up 94.4% to $20.7 million on the Protein Pop launch (Protein Pop is 68% of Rise sales).
- Core Nutritional SG&A fell to 33.9% of segment sales on cost realignment savings; Hiya SG&A jumped to 86.2% of segment sales on higher advertising.
- Cash $178.9 million and no outstanding debt on the $75 million credit facility; China remitted a $62.3 million dividend to the US; credit covenants were eased by an amendment on September 30, 2026.
- Sale of the Castle Hill (Australia) facility settled October 12, 2026: net proceeds about $16,080 thousand and an expected pre-tax gain of $8,230 thousand in Q4 2026.
- USANA Q4 and fiscal 2025 earnings call (February 18, 2026)
- First call after Kevin Guest's return as CEO; he says the clear message from leaders and Brand Partners is "we must move with greater speed, focus, relevancy, and precision".
- Six priorities: global brand positioning as a "modern, science-driven nutritional products company" through an omnichannel platform, customer and Brand Partner experience, sales momentum, product innovation, operational efficiency, and accountability.
- FY2026 outlook: consolidated net sales growth of about 4% at the midpoint, driven by the ventures Rise Wellness and Hiya; Rise expected to be roughly breakeven.
- Technology modernisation will move to best-in-practice third-party platforms and AI; the incremental investment is not yet in the outlook.
- Inventory rose $35 million (48%) to $107 million, about 80% of it for Rise Wellness (Protein Pop at Costco) and Hiya (Target, Canada, UK, in-house manufacturing).
- Cost realignment affected about 10% of the workforce, with roughly $10 million of net savings, mainly in SG&A.
- Effective tax rate guidance 55%-60% because revenue and costs sit in different geographies; Guest frames the omnichannel push as diversifying revenue away from China.
- USANA Q3 2026 earnings call (November 4, 2026)
- Guest calls Q3 2026 "a mixed quarter"; the strategy is to evolve USANA "from a single channel direct selling company into a diversified omnichannel health and wellness company built on consumer acquisition and loyalty".
- Core nutrition: active customers down 8% year over year, Greater China drove most of the sequential decline; Southeast Asia Pacific grew net sales 2% after a 13% decline the prior quarter.
- Growing active customers is the top priority, through brand investment, incentive refinements and product innovation launching in 2027 (women's and kids' initiatives).
- Hiya: active monthly subscribers up 18% sequentially (about 29,500 net adds) as acquisition costs fell; Target and Amazon sales more than doubled from Q2; Hiya sales outlook raised to $130 million; club retail entry planned early Q1 2027.
- Rise Wellness: outlook lowered again because club orders are lumpy; Protein Pop Balance launched at Target; about 4,100 Target and grocery stores by year end.
- Outlook (Hekking): net sales approaching $900 million, adjusted EBITDA about $77 million (previously $80.5 million); Core Nutritional sales about $740 million.
- Cash: $45 million operating cash flow and $36 million free cash flow year to date; $179 million cash and no debt.
- Brand Partner plan: adjustments to qualification criteria and payout timing to drive retention, phased in through 2027.
Questions about USANA Health Sciences
What does USANA Health Sciences do?
It develops and manufactures science-based nutritional supplements, functional foods and personal care products, sold through direct selling (Brand Partners), Hiya's direct-to-consumer subscriptions, Amazon and retail.
What is USANA's revenue?
FY2025 net sales were $925.3 million. The FY2026 outlook is net sales approaching $900 million.
How many employees does USANA have?
Approximately 1,570 employees (FTE) in 22 countries, 41% in the United States and 28% in China.
Who leads USANA?
Kevin Guest reassumed the CEO role in January 2026 and remains Chairman; G. Douglas Hekking is CFO and Walter Noot is COO.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)